Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A compound, phenyl technology, applied in the field of drug therapy, can solve the problem of affecting the phenotype of adjacent glomerular mesangial cells
Inactive Publication Date: 2001-08-29
WARNER-LAMBERT CO
View PDF4 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Although MMP-2 specifically degrades the outer ECM, it c
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
[0305] Step (a): Preparation of 6,7,8,9-tetrahydro-oxyfluorene-3-sulfonic acid
[0306] To a solution of tetrahydrofluorene (4 g, 0.023 mol) in dichloroethane (50 mL) was added sulfur dioxide-DMF complex (6 g, 0.039 mol) in one portion. The reaction mixture was refluxed for 14 hours, cooled and concentrated in vacuo. The resulting crude liquid was dissolved in warm diethyl ether / ethanol and precipitated upon cooling. The solid was collected by filtration, washed with diethyl ether and dried in vacuo to afford the title compound as a pink solid (2.3 g, 40%). 1 HNMR (CDCl 3 )δ7.9(s,1H),7.7(d,1H),7.4(d,1H),2.8(m,2H),2.6(m,2H),2.0-1.8(m,4H)ppm.
[0307] Step (b): Preparation of 6,7,8,9-tetrahydro-oxyfluorene-3-sulfonyl chloride
[0308] 6,7,8,9-Tetrahydrooxyfluorene-3-sulfonic acid (2.1 g, 8.3 mmol) was suspended in thionyl chloride (25 mL) and stirred at room temperature for 6 hours. The so...
[0317] (S) 2-(6,7,8,9-Tetrahydro-oxyfluorene-3-sulfonylamino)-succinic acid; mp 176-179°C. 1 HNMR (CDCl 3 / DMSO -d 6 )δ7.8(s,1H),7.6(d,1H),7.4(d,1H),5.9(d,1H),3.9(m,1H),2.9-2.5(m,7H),1.9-1.7 (m, 4H)ppm. Using a method similar to that described in Example 1, but replacing D-valine and tert-butyl ester with L-homophenylalanine and methyl ester, and utilizing alkali hydrolysis to prepare the following Compound:
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
Tricyclic sulfonamide compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.
Description
Background of the invention [0001] The present invention relates to novel tricyclic sulfonamide compounds and their derivatives used as medicines, their preparation methods, pharmaceutical compositions comprising these compounds and pharmaceutically acceptable carriers, and medical treatment methods. The novel compounds of the present invention are inhibitors of matrix metalloproteinases such as gelatinase A (MMP-2), collagenase-3 (MMP-13) and stromelysin-1 (MMP-2). More specifically, the novel compounds of the present invention are useful in the treatment of atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilatation, restenosis, periodontal disease, corneal ulcer, burn management, decubitus ulcer, wound repair , cancer, inflammation, pain, arthritis, osteoporosis, multiple sclerosis, kidney disease, and other autoimmune or inflammatory diseases that depend on tissue invasion by leukocytes or other activated mobile cells. In addition, the comp...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more